Compare Cytokinetics Inc (CYTK) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Match Group Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Match Group Inc trades at $41.48 (market cap $9.37B). The key difference: Cytokinetics Inc and Match Group Inc are close in size by market cap, and Match Group Inc pays a 1.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Match Group Inc for 115 Days on average.
| CYTK | MTCH | |
|---|---|---|
Market Cap | $8.50B | $9.37B |
Volume | 2,395,556 | 2,544,041 |
Sector | Health | Media |
52-Week High | $87.26 | $44.40 |
52-Week Low | $54.76 | $28.90 |
Typical Hold Time | 19 Days | 115 Days |
Enterprise Value | $8.60B | $12.34B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Match Group (MTCH) trades at $41.50, up 2.17% with a bullish technical outlook. The stock shows strong fundamentals with 74.8% gross margins and consistent earnings beats in recent quarters. Revenue remains stable at $3.5B while net income margin improved to 20.17% in 2025. Analyst consensus is bullish with a $42.29 price target, and institutional activity shows continued interest despite recent selling by some advisors.
MTCH presents a compelling investment case with reasonable valuation (P/E 14.48) and strong cash flow generation. Key risks include high debt levels ($3.85B) and competitive pressures in the dating app market. The company's product innovation and Hinge's growth provide upside potential, though execution risks and market saturation concerns warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
